Artivion | CRY - Selling And Administration Expenses

Stock Price
38.33
Daily Change
0.33 0.87%
Monthly
-13.50%
Yearly
35.63%
Q1 Forecast
37.14

Artivion reported $50.02M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Accuray USD 127.32M 500.16M Sep/2025
AngioDynamics USD 35.99M 14K Feb/2025
Artivion USD 50.02M 697K Sep/2024
AtriCure USD 78.34M 109K Dec/2025
Baxter International USD 761M 53M Dec/2025
Becton, Dickinson and Co. USD 1.39B 27M Dec/2025
Boston Scientific USD 1.83B 93M Dec/2025
Edwards Lifesciences USD 602.9M 88.3M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Integra LifeSciences USD 169.05M 10.84M Sep/2025
J&J USD 6.75B 831M Dec/2025
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 112.21M 1.1M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
ResMed USD 278.4M 19.2M Dec/2025
Stryker USD 2.14B 150M Dec/2025
Surmodics USD 14.58M 2.05M Sep/2024
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 281.76M 66.68M Sep/2025
Terumo JPY 105.26B 7.38B Dec/2025
Trinity Biotech USD 6.19M 2.18M Sep/2025